HOME >> MEDICINE >> NEWS
Insurance incentives might help smokers quit, study says

Health insurance that pays the full cost of smoking-cessation treatments can increase quit rates, compared to benefit plans that pick up only part of the tab or that offer no cessation benefits at all, according to a new review of studies.

Smokers receiving full benefits were one-and-a-half times more likely to quit successfully and nearly one-and-a-half times more likely to try quitting than those receiving no benefit, according to review authors Janneke Kaper of Maastricht University in the Netherlands and colleagues.

The actual increase in quit rates was slight, however. In studies where a full benefit was compared to no benefit, abstinence rates among smokers rose 2 percentage points, Kaper says.

"In this economically minded time, determining the effectiveness of an intervention is no longer enough to justify its use," Kaper says. "As health care costs increase and resources are limited, it is also important to determine whether financial support for smoking-cessation treatment is cost-effective."

The "relatively low costs" of providing full benefits for smoking cessation varied between $260 and $2,330 per quitter, compared to partial or no benefits, the researchers say.

The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Previous research shows that smoking-cessation treatment, including counseling, nicotine replacement products and the antidepressant drug bupropion can increase the chances that a smoker will give up the habit.

But "costs are a significant barrier to the use of smoking-cessation treatment. Healthcare providers may be deterred from offering treatment if they do not receive reimbursement, and patients may be deterred
'"/>

Contact: Janneke Kaper
janneke.kaper@hag.unimaas.nl
Center for the Advancement of Health
22-Feb-2005


Page: 1 2 3

Related medicine news :

1. Insurance Restrictions On Acne Drug Are Outmoded And Costly
2. Disabilities Dont Raise Insurance Costs
3. Factors Other Than Race Explain Whether Men In Study Had Health Insurance And Received Health Care
4. Mutual Insurance Pool Could Improve Transplant Organ Shortage
5. Dermatologists Recommend Raising Age for Insurance Coverage for Acne Drugs to Age 40 -- or Beyond
6. Newly discovered pathway might help in design of cancer drugs
7. Protein that promotes survival of stem cells might be key to poor leukemia prognosis
8. Animal studies show stem cells might make biological pacemaker
9. Temporary weight gain over the winter holidays... might be a good thing
10. Stem cells repair skills might be link to cancer
11. Looking for the secret to a healthier diet? Part of the answer might be at church, study finds

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Insurance incentives might help smokers quit study says

(Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
(Date:1/14/2014)... Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre partner ... Virginia is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is ... husband, Dr. Cole Taylor , are avid scuba divers. "As ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
Cached News: